Clinical trials: Cellular Rejection
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
End Stage Renal Disease, Antibody Mediated Rejection
Belatacept in Kidney Transplantation of Moderately Sensitized Patients
The purpose of this study is to evaluate the safety and effectiveness of an immunosuppressive medication, Belatacept, as a replacement for a calcineurin inhibitor, in combination with a standard of care regimen of…
- Trial name
- BelatPilot (NCT02130817)
- Testing
- Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Heart Transplantation, Rejection Heart Transplant
Evaluation of the Added Clinical Value of Donor-derived Cell-free DNA for the Monitoring of Cardiac Allograft Rejection.
The goal of this observational study is to assess the clinical added value of donor-derived cell-free DNA (dd-cfDNA) to monitor cardiac allograft rejection.
- Trial name
- HEART-FREE (NCT06740578)
- Where
- 2 sites in France
- Volunteers
- 320 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Chronic Rejection of Liver Transplant
Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance
The first trial will involve the generation of donor alloantigen-specific CD4+CD25+ Tregs from peripheral blood of pre-transplant patients, the administration of the CD4+CD25+ Tregs (1 x 106 cells/kg) at several intervals (for…
- Trial name
- Treg (NCT01624077)
- Testing
- Regulatory T cells
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Kidney Transplantation
Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation
The purpose of this study is to determine whether bortezomib is effective in the treatment of acute cellular rejection after kidney transplantation.
- Trial name
- NCT02351427
- Testing
- Bortezomib, Steroid
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
End Stage Renal Disease
Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients
Regulatory CD4+CD25+ T cells (Treg) derived from the thymus and/or peripheral tissues have been demonstrated to broadly control T cell reactivity (14).
- Trial name
- TRACT (NCT02145325)
- Testing
- Expanded Tregs
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Lung Transplant Rejection
Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Lung transplantation is a consolidated treatment in selected patients with end-stage respiratory diseases; however, acute rejection remains an important cause of lung allograft loss and a risk factor for chronic allograft…
- Trial name
- NGS-ACRL (NCT05260372)
- Testing
- Quantification of donor-derived cell-free DNA
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Immunity, Cellular
Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients
The study will prospectively determine the clinical utility of non-pathogen specific cellular immunity assessment using the Quantiferon-Monitor to quantify the degree of immunosuppression.
- Trial name
- QTF-Monitor (NCT02560857)
- Testing
- Quantiferon-Monitor assay
- Where
- Canada
- Volunteers
- 151 people
- Sponsor
- Deepali Kumar
Renal Transplant Rejection, Immune Repertoire
ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation
In this study, the investigators will establish a workflow to generate unique patterns of the donor-reactive T cell repertoire using mixed lymphocyte reactions to select alloreactive T cell clones prior to transplantation Tissue…
- Conditions
- Renal Transplant Rejection, Immune Repertoire, Transplant; Complication, Rejection, Alloreactivity
- Trial name
- ALL-T-COPIES (NCT03422224)
- Testing
- Mixed lymphocyte reaction
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Liver Transplant Rejection
Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration
This is a randomized controlled trial in which the safety and feasibility of cell therapy medicinal product shall be measured by comparing the variables of the response after treatment compared to baseline prior to…
- Trial name
- NCT01745731
- Testing
- Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Graft Failure
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
Major Objectives A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients who have rejected (<5% T Cell Chimerism) a previous allogeneic hematopoietic stem cell graft by using an…
- Trial name
- NCT00472329
- Testing
- Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors, fludarabine, TBI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Colorado Blood Cancer Institute
Rejection; Transplant, Liver, Liver Failure
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal.
- Conditions
- Rejection; Transplant, Liver, Liver Failure, Liver Diseases
- Trial name
- LIBERATE (NCT05234190)
- Testing
- QEL-001
- Where
- 10 sites in Belgium, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- Quell Therapeutics Limited
Lung Transplant Rejection
Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation
To investigate safety of treatment with allogeneic adipose tissue-derived mesenchymal stromal cells (ASCs) in patients undergoing lung transplantation, to evaluate whether the treatment can reduce host immunological reaction…
- Trial name
- NCT04714801
- Testing
- adipose derived mesenchymal stromal cells, Saline
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Rejection, Graft Loss
Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients
This study will test whether selected allogeneic bone marrow derived MSCs are safe by assessing the composite end point Biopsy Proven Acute Rejection (BPAR)/ graft loss at 12 months.
- Trial name
- Neptune (NCT02387151)
- Testing
- mesenchymal stromal cells
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Leiden University Medical Center
Lung Transplant Rejection
Cell-free DNA as a Biomarker After Lung Transplantation
The purpose of this investigation is to determine the association of the fraction of donor-derived cell-free DNA in plasma and lung fluid samples with acute rejection as proven by biopsy in lung transplant recipients.
- Trial name
- NCT04271267
- Testing
- No Intervention
- Volunteers
- 126 people
- Sponsor
- Duke University
End Stage Kidney Disease, Immunological Tolerance
Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants
The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function…
- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Trial name
- NCT05525507
- Testing
- Conditioning and Stem cell infusion
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
End Stage Renal Disease, Renal Transplant
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
Induction therapy with antibodies is administered during transplant surgery and for a short period of time following transplant surgery in an effort to render the immune system less able to mount an initial rejection response.
- Trial name
- NCT01154387
- Testing
- Anti-Thymocyte Globulin, TOL101, Steroids
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- Tolera Therapeutics, Inc
Transplant Rejection, Kidney Transplantation
Study of Tolerant Kidney Transplant Recipients
The purpose of this multi-center (observational) registry study is to establish a database of clinical and laboratory information that may help to identify any unique characteristics of tolerant participants that differ from…
- Conditions
- Transplant Rejection, Kidney Transplantation, Renal Transplantation, Renal Transplant
- Trial name
- FACTOR (NCT01338779)
- Where
- 4 sites in United States
- Volunteers
- 197 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hematological Malignancies
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning from HLA-mismatched PBSC or cord blood: a Pilot…
- Trial name
- NCT00504803
- Testing
- Mesenchymal stem cell infusion
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Liege